Kura Oncology, Inc. (NASDAQ:KURA) Expected to Post Earnings of -$0.54 Per Share

Wall Street brokerages expect Kura Oncology, Inc. (NASDAQ:KURA) to report ($0.54) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Kura Oncology’s earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.62). Kura Oncology posted earnings of ($0.45) per share in the same quarter last year, which suggests a negative year over year growth rate of 20%. The business is scheduled to issue its next earnings results on Wednesday, February 23rd.

On average, analysts expect that Kura Oncology will report full year earnings of ($2.01) per share for the current year, with EPS estimates ranging from ($2.10) to ($1.98). For the next financial year, analysts forecast that the business will post earnings of ($2.27) per share, with EPS estimates ranging from ($2.85) to ($1.99). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Kura Oncology.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, November 4th. The company reported ($0.50) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.04. During the same period in the prior year, the business earned ($0.42) EPS.

Several research firms have commented on KURA. Zacks Investment Research raised Kura Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, October 12th. SVB Leerink boosted their target price on Kura Oncology from $40.00 to $41.00 and gave the stock an “outperform” rating in a report on Friday, August 6th. HC Wainwright dropped their target price on Kura Oncology from $43.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday. Wedbush reissued an “outperform” rating on shares of Kura Oncology in a report on Monday, November 8th. Finally, Credit Suisse Group dropped their target price on Kura Oncology from $42.00 to $40.00 and set an “outperform” rating on the stock in a report on Friday, August 6th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $42.71.

Shares of NASDAQ KURA traded down $2.58 during mid-day trading on Thursday, hitting $14.02. 6,681,951 shares of the stock traded hands, compared to its average volume of 677,911. Kura Oncology has a 52 week low of $12.32 and a 52 week high of $43.00. The company has a market cap of $933.12 million, a price-to-earnings ratio of -7.30 and a beta of 1.58. The stock has a fifty day moving average price of $18.24 and a 200-day moving average price of $19.58.

Several large investors have recently made changes to their positions in KURA. BlackRock Inc. increased its position in Kura Oncology by 0.8% during the third quarter. BlackRock Inc. now owns 5,001,416 shares of the company’s stock valued at $93,678,000 after acquiring an additional 39,035 shares during the last quarter. Avoro Capital Advisors LLC increased its position in Kura Oncology by 3.5% during the second quarter. Avoro Capital Advisors LLC now owns 4,140,000 shares of the company’s stock valued at $86,319,000 after acquiring an additional 140,000 shares during the last quarter. State Street Corp increased its position in Kura Oncology by 14.9% during the second quarter. State Street Corp now owns 3,254,642 shares of the company’s stock valued at $67,859,000 after acquiring an additional 420,992 shares during the last quarter. Invesco Ltd. increased its position in Kura Oncology by 96.8% during the third quarter. Invesco Ltd. now owns 3,000,140 shares of the company’s stock valued at $56,194,000 after acquiring an additional 1,475,350 shares during the last quarter. Finally, Suvretta Capital Management LLC increased its position in Kura Oncology by 48.3% in the third quarter. Suvretta Capital Management LLC now owns 2,460,202 shares of the company’s stock worth $46,080,000 after buying an additional 801,496 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias.

See Also: Trading Strategy Methods for Individual Investors

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.